Browse studies
Find your next paid study
123 recruiting studies matching your filters
Phase 2
Prospective Randomized Phase II Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL
This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic …
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Estimated
~$10 – $6,250
Ohio State University Comprehensive Cancer CenterNCT05336812
Phase 1
Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseas…
Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaAcute Lymphocytic Leukemia
Estimated
~$10 – $6,250
Baylor College of MedicineNCT01853631
Phase 2
Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These …
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Estimated
~$10 – $5,625
VA Office of Research and DevelopmentNCT06520098